Peptides · Peptide comparison
Capromorelin vs CJC-1295 with DAC
An oral ghrelin agonist originally developed by Pfizer that stimulates growth hormone and appetite. FDA-approved for veterinary use (Entyce and Elura) and investigated in human trials for age-related muscle wasting and appetite support.
Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.
- Growth Hormone
- Growth Hormone
At a glance
Quick comparison
Efficacy
Benefit ratings
GH & IGF-1 Stimulation
Physical Function
Oral Convenience
GH Elevation
Convenience
Recovery Support
Technical data
Compound specifications
Capromorelin
- Molecular formula
- C28H35N5O4
- Molecular weight
- 505.6 g/mol
- Half-life
- About 1.2 hours in dogs (ENTYCE label)
- Bioavailability
- 44% oral in dogs and 65% in rats; no human figure published on this page
- CAS number
- 193273-66-4
CJC-1295 with DAC
- Molecular formula
- C165H269N47O46
- Molecular weight
- 3647.28 g/mol
- Half-life
- 6-8 days
- Bioavailability
- ~100% (subcutaneous)
- CAS number
- 863288-34-0
Protocols
Dosing compared
Capromorelin
Oral
- 3 mgTwice daily · Initial weeksOne of the lower doses tested in the year-long study in older adults; raised growth hormone and IGF-1 [1].
- 10 mgOnce daily at bedtime · OngoingA simple once-daily bedtime dose used in the human trial that improved lean body mass [1].
- 10 mgTwice daily · Up to 12 months in the trialThe highest daily amount studied in older adults (20 mg/day). The trial reported results for the pooled treatment groups, not the largest gains for this dose [1].
CJC-1295 with DAC
Subcutaneous
- 1 mg (1000 mcg)Once weekly · 2-4 weeksA starting dose used in practice. The DAC version is long-acting (about a 6-8 day half-life), so weekly dosing keeps growth hormone and IGF-1 raised. In the Phase 1 trial a single dose raised GH for 6+ days and IGF-1 for up to 11 days. [2]
- 2 mg (2000 mcg)Once weekly (or split twice weekly) · 8-12 weeksThe common maintenance dose, roughly in line with the 30-60 mcg/kg weekly range studied in the Phase 1 trial. [1][2] In the ascending-dose trials, single injections raised mean GH 2- to 10-fold for six or more days and IGF-I 1.5- to 3-fold for 9-11 days; 30 and 60 µg/kg doses were the best tolerated [2].
- 2 mg per doseTwice weekly · 8-12 weeksA higher total weekly amount split into two doses, used by experienced users; near the top of the 30-60 mcg/kg weekly range from the clinical study. [2]
Applications
Best suited for
Capromorelin
- Age-Related Muscle Wasting
- Capromorelin showed significant improvements in physical function — including tandem walk and stair climb — in elderly adults, making it a strong candidate for combating sarcopenia.
- Appetite Stimulation
- As an FDA-approved veterinary appetite stimulant, capromorelin has extensive real-world evidence for boosting food intake and body weight in mammals.
- Growth Hormone Research
- One of the best-studied oral ghrelin agonists with human Phase 2 data, offering researchers a well-characterized tool for studying GH/IGF-1 pathways.
CJC-1295 with DAC
- Growth Hormone Optimization
- CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
- Muscle Building and Recovery
- By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
- Anti-Aging and Longevity
- Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
- Body Composition Improvement
- The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
- Convenient Weekly Dosing
- Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.
Safety profile
Side effects
Capromorelin
Common
- Appetite stimulation
- Fluid retention and weight gain
Uncommon
- Joint and muscle aches
- Fatigue or lethargy
- Peripheral edema (swelling)
Serious
- Hyperglycemia
CJC-1295 with DAC
Common
- Injection site reactions
- Water retention
- Flushing
- Tingling sensation
Uncommon
- Headaches
- Fatigue or lethargy
- Joint discomfort
Serious
- Carpal tunnel symptoms
- Blood glucose elevation
Research status
Safety & evidence
Capromorelin
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Not approved for human use. FDA-approved for veterinary use only: ENTYCE (appetite stimulation in dogs, 2016) and ELURA (weight loss in cats with chronic kidney disease, 2020); both labels state "not for use in humans".
- Safety overview
- Capromorelin was generally well-tolerated in Phase 2 human trials involving nearly 400 elderly participants. Most side effects were mild to moderate. Its FDA-approved veterinary use provides additional long-term safety data in mammalian species.
Contraindications
- Active cancer or history of cancer (GH may stimulate growth)
- Uncontrolled diabetes or severe metabolic disorders
- Severe liver or kidney disease
- Pregnancy and lactation
CJC-1295 with DAC
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.
Contraindications
- Active cancer or history of malignancy
- Pregnancy or breastfeeding
- Pituitary tumors or disorders
- Diabetic retinopathy
- Uncontrolled diabetes
Decision guide
Which is right for you?
Capromorelin
Choose Capromorelin if…
- Stimulating growth hormone production in elderly adults
- Supporting appetite and weight gain in wasting conditions
- Improving muscle mass and physical performance
- Anti-aging and longevity optimization
CJC-1295 with DAC
Choose CJC-1295 with DAC if…
- Boosting natural growth hormone production
- Building lean muscle mass
- Improving body composition
- Anti-aging and longevity